KNSA vs. INVA, PNT, MRUS, PRTC, COLL, BLTE, COGT, ENTA, KURA, and MCRB
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Innoviva (INVA), POINT Biopharma Global (PNT), Merus (MRUS), PureTech Health (PRTC), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), Cogent Biosciences (COGT), Enanta Pharmaceuticals (ENTA), Kura Oncology (KURA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Kiniksa Pharmaceuticals vs.
Innoviva (NASDAQ:INVA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Innoviva has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kiniksa Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals and 2 mentions for Innoviva. Kiniksa Pharmaceuticals' average media sentiment score of 1.60 beat Innoviva's score of 0.81 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
43.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 0.9% of Innoviva shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Innoviva received 133 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 63.71% of users gave Kiniksa Pharmaceuticals an outperform vote while only 57.74% of users gave Innoviva an outperform vote.
Kiniksa Pharmaceuticals has a net margin of 83.28% compared to Innoviva's net margin of 64.56%. Innoviva's return on equity of 18.81% beat Kiniksa Pharmaceuticals' return on equity.
Innoviva presently has a consensus price target of $15.17, suggesting a potential upside of 36.02%. Kiniksa Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 79.37%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Innoviva.
Innoviva has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals beats Innoviva on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
